Gibson, Dunn & Crutcher advised Arrowhead Pharmaceuticals, Inc. on the transaction, while Mintz, Levin, Cohn, Ferris, Glovsky, and Popeo and Proskauer Rose advised Sixth Street. Arrowhead...
You must be a Standard 1 Year member to access this content.
Skadden advised Eyebiotech Limited, while Gibson, Dunn & Crutcher advised Merck the deal. Merck, known as MSD outside of the United States and Canada, and Eyebiotech...
You must be a Standard 1 Year member to access this content.
Gibson, Dunn & Crutcher advised BTG Pactual on the deal. BTG Pactual announced its financing in the buyout of Fortress Investment Group, a global investment manager...
You must be a Standard 1 Year member to access this content.
Gibson, Dunn & Crutcher advised PAR Technology Corporation on the transaction. PAR Technology Corporation (NYSE: PAR) (the “Company” or “PAR”) announced it has completed the acquisition of Stuzo...
You must be a Standard 1 Year member to access this content.
Gibson, Dunn & Crutcher advised PAR Technology Corporation on the transaction, and Winston & Strawn represented Longshore Capital Partners, as the Seller Representative. PAR Technology Corporation...
You must be a Standard 1 Year member to access this content.
Gibson, Dunn & Crutcher LLP advised Merck on its acquisition of Caraway Therapeutics, Inc. Merck (NYSE: MRK), known as MSD outside of the United States and...
You must be a Standard 1 Year member to access this content.
Gibson, Dunn & Crutcher LLP advised Appian Capital Advisory LLP on the matter. Appian Capital Advisory LLP, the investment advisor to long-term value focused private capital funds that...
You must be a Standard 1 Year member to access this content.
